soo-ma-TRIP-tan 
Absorption: Well absorbed (97%) after subcut administration. Absorption after oral administration is incomplete and significant amounts undergo substantial hepatic metabolism, resulting in poor bioavailability (14%). Well absorbed after intranasal administration.
Distribution: Does not cross the blood-brain barrier. Remainder of distribution not known.
Metabolism/Excretion: Mostly metabolized (80%) by the liver.
Half-life: 2 hr.
Contraindicated in:
Use Cautiously in:
Exercise Extreme Caution in:
All adverse reactions are less common after oral administration
CV: MI, angina, chest pressure, chest tightness, coronary vasospasm, ECG changes, transient hypertension.
Derm: tingling, warm sensation, burning sensation, cool sensation, flushing.
EENT: alterations in vision, nasal sinus discomfort, throat discomfort.
GI: abdominal discomfort, dysphagia.
Local: injection site reaction.
MS: jaw discomfort, muscle cramps, myalgia, neck pain, neck stiffness.
Neuro: numbness , dizziness, vertigo, anxiety, drowsiness, fatigue, feeling of heaviness, feeling of tightness, headache, malaise, strange feeling, tight feeling in head, weakness.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
Drug-Natural Products:
Hepatic Impairment
Therapeutic Classification: vascular headache suppressants
Pharmacologic Classification: five ht1 agonists
(Generic available)
(relief of migraine)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | within 30 min | 2–4 hr | up to 24 hr |
| Subcut | 30 min | up to 2 hr | up to 24 hr |
| Nasal | within 60 min | 2 hr | unknown |
2 hr. Do not administer 2nd dose if no relief was provided by 1st dose without consulting health care professional.NDC Code*